Down-regulation of RhoE is associated with progression and poor prognosis in hepatocellular carcinoma

Journal of Surgical Oncology

Volumn 105, Issue 7, 2012, Pages 699-704

  Luo, Hesan ^a,b   Dong, Zhongyi ^a   Zou, Jinjin ^a   Zeng, Qin ^a   Wu, Dehua ^a   Liu, Li ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SHANTOU CENTRAL HOSPITAL   (China)

Author keywords

hepatocellular carcinoma; immunohistochemistry; prognosis; RhoE

Indexed keywords

ALPHA FETOPROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOE GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LIVER CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL TIME;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; PROGNOSIS; RHO GTP-BINDING PROTEINS;

EID: 84859910902     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23019     Document Type: Article

References (25)

1. Pastorelli D, Cartei G, Zustovich F, et al.: Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature. Ann Oncol 2006; 17: v153-v157. (Pubitemid 43985226)
2. Shariff MI, Cox IJ, Gomaa AI, et al.: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009; 3: 353-367.
3. Tung-Ping Poon R, Fan ST, Wong J,: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24. (Pubitemid 30456545)
4. Arii S, Yamaoka Y, Futagawa S, et al.: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-1229.
5. Chen F,: Molecular signature of hepatocellular carcinoma, hope or hype in prognosis and therapy. Semin Cancer Biol 2011; 21: 1-3.
6. Kudo M,: Management of hepatocellular carcinoma: From prevention to molecular targeted therapy. Oncology 2010; 78: 1-6.
7. Ellenbroek SI, Collard JG,: Rho GTPases: Functions and association with cancer. Clin Exp Metastasis 2007; 24: 657-672. (Pubitemid 50002983)
8. Pasqualucci L, Neumeister P, Goossens T, et al.: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412: 341-346. (Pubitemid 32691848)
9. Preudhomme C, Roumier C, Hildebrand MP, et al.: Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma. Oncogene 2000; 19: 2023-2032. (Pubitemid 30229415)
10. Fritz G, Just I, Kaina B,: Rho GTPases are over-expressed in human tumors. Int J Cancer 1999; 81: 682-687. (Pubitemid 29214373)
11. Fritz G, Brachetti C, Bahlmann F, et al.: Rho GTPases in human breast tumours: Expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002; 87: 635-644.
12. Kamai T, Yamanishi T, Shirataki H, et al.: Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 2004; 10: 4799-4805. (Pubitemid 38955533)
13. Riou P, Villalonga P, Ridley AJ,: Rnd proteins: Multifunctional regulators of the cytoskeleton and cell cycle progression. BioEssays 2010; 32: 986-992.
14. Akashi H, Han HJ, Iizaka M, et al.: Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer 2000; 88: 873-880.
15. Wang D, Dubois RN,: The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-788.
16. Bektic J, Pfeil K, Berger AP, et al.: Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate 2005; 64: 332-340. (Pubitemid 41193245)
17. Bektic J, Wrulich OA, Dobler G, et al.: Identification of genes involved in estrogenic action in the human prostate using microarray analysis. Genomics 2004; 83: 34-44. (Pubitemid 37518258)
18. Cuiyan Z, Jie H, Fang Z, et al.: Overexpression of RhoE in Non-small Cell Lung Cancer (NSCLC) is associated with smoking and correlates with DNA copy number changes. Cancer Biol Ther 2007; 6: 335-342. (Pubitemid 47328299)
19. Zhang C, Zhou F, Li N, et al.: Overexpression of RhoE has a prognostic value in non-small cell lung cancer. Ann Surg Oncol 2007; 14: 2628-2635. (Pubitemid 47389581)
20. Kononen J, Bubendorf L, Kallioniemi A, et al.: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847. (Pubitemid 28331029)
21. Baig JA, Alam JM, Mahmood SR, et al.: Hepatocellular carcinoma (HCC) and diagnostic significance of A-fetoprotein (AFP). J Ayub Med Coll Abbottabad 2009; 21: 72-75.
22. Matsuda M, Asakawa M, Amemiya H, et al.: Lens culinaris agglutinin-reactive fraction of AFP is a useful prognostic biomarker for survival after repeat hepatic resection for HCC. J Gastroenterol Hepatol 2010; 26: 731-738.
23. Yamamoto K, Imamura H, Matsuyama Y, et al.: AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010; 45: 1272-1282.
24. Ding Y, Chen B, Wang S, et al.: Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients. Int J Cancer 2009; 124: 653-658.
25. Yang W, Lv S, Liu X, et al.: Up-regulation of Tiam1 and Rac1 correlates with poor prognosis in hepatocellular carcinoma. Jpn J Clin Oncol 2010; 40: 1053-1059.